Acorda therapeutics reports q3 results

Q3 non-gaap loss per share $0.46.q3 gaap loss per share $5.55.q3 earnings per share estimate $-0.51 -- refinitiv ibes data.for quarter ended september 30, 2019, company reported inbrija net revenue of $4.9 million.qtrly ampyra net revenue of $37.6 million compared to $137.8 million for same quarter in 2018.at september 30, 2019, company had cash, cash equivalents and short-term investments of $253 million.research and development expenses for full year 2019 are expected to be $55 - $60 million.research and development expenses for full year 2020 are expected to be $20 - $25 million.total operating expenses in 2020 are estimated to be about $60 million less than in 2019.qtrly total revenues $47.7 million versus $142.8 million.q3 earnings per share view $-0.51, revenue view $44.7 million -- refinitiv ibes data.
ACOR Ratings Summary
ACOR Quant Ranking